ResearcherUniversity Hospitals of Leicester NHS TrustNo recent work listed
Giuseppe Garcea
Matched on ORCID iD 0000-0001-9682-1708; OpenAlex author ID A5027108487. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 30
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper
Papers 6
- PET-CT in the staging of potentially resectable pancreatic cancer Last author DOI 10.21203/rs.3.rs-3079385/v1↗
- Significance of indeterminate pulmonary nodules in resectable pancreatic adenocarcinoma-a review. Last author DOI 10.1007/s00423-020-02049-w↗
- Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. Co-author DOI 10.1016/j.hpb.2021.03.003↗
- Treatment Access and Survival Amongst British Asians with Pancreatic Cancer. Last author DOI 10.1007/s00268-016-3707-7↗
- Targeting pancreatic cancer using a combination of gemcitabine with the omega-3 polyunsaturated fatty acid emulsion, Lipidem™. Co-author DOI 10.1002/mnfr.201500755↗
- Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. Co-author DOI 10.1007/s00268-011-0984-z↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ashley Robert Dennison · 5 shared papers, 2011–2023 · strength 0.63
- Paper Significance of indeterminate pulmonary nodules in resectable pancreatic adenocarcinoma-a review. DOI 10.1007/s00423-020-02049-w↗
- Paper PET-CT in the staging of potentially resectable pancreatic cancer DOI 10.21203/rs.3.rs-3079385/v1↗
- Paper Treatment Access and Survival Amongst British Asians with Pancreatic Cancer. DOI 10.1007/s00268-016-3707-7↗
- John Isherwood · 2 shared papers, 2017–2023 · strength 0.29
- Li Lian Kuan · 1 shared paper, 2021 · strength 0.22
- Neil Bhardwaj · 1 shared paper, 2023 · strength 0.20
- Tareq Alsaoudi · 1 shared paper, 2023 · strength 0.20
- Jonathan Haqq · 1 shared paper, 2016 · strength 0.08
- Iain Stephen Tait · 1 shared paper, 2021 · strength 0.08
- Duncan R.C. Spalding · 1 shared paper, 2021 · strength 0.08
- James Michael Halle-Smith · 1 shared paper, 2021 · strength 0.08
- Jawad Elsayed Ahmad · 1 shared paper, 2021 · strength 0.08
- Ali Raza Arshad · 1 shared paper, 2021 · strength 0.08
- Nicola de Liguori Carino · 1 shared paper, 2021 · strength 0.08
- Andreas A. Prachalias · 1 shared paper, 2021 · strength 0.08
- Samir Pathak · 1 shared paper, 2021 · strength 0.08
- Robert Peter Sutcliffe · 1 shared paper, 2021 · strength 0.08
- Sivesh Kathir Kamarajah · 1 shared paper, 2021 · strength 0.08
- Stephen J. Wigmore · 1 shared paper, 2021 · strength 0.08
- Ricky Harminder Bhogal · 1 shared paper, 2021 · strength 0.08
- Somaiah Aroori · 1 shared paper, 2021 · strength 0.08
- Bilal A. Al-Sarireh · 1 shared paper, 2021 · strength 0.08
- Krishna V Menon · 1 shared paper, 2021 · strength 0.08
- Jonathan R.E. Rees · 1 shared paper, 2021 · strength 0.08
- David A. Stell · 1 shared paper, 2021 · strength 0.08
- Nigel Balfour Jamieson · 1 shared paper, 2021 · strength 0.08
- Siobhan C. McKay · 1 shared paper, 2021 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.